Syndex Bio, a biotechnology company focused on molecular diagnostics, has introduced its new mcPCR (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) conference in Orlando, Florida. The technology allows for the high-fidelity copying of both DNA methylation and the four-base genetic code during DNA amplification. This addresses a key limitation of traditional PCR methods, which cannot amplify DNA methylation patterns important for detecting diseases such as cancer.
The mcPCR platform is designed to simplify and speed up the analysis of methylated DNA. It aims to improve testing in clinical samples, especially for non-invasive and small-sample biopsies used in early disease detection and monitoring recurrence.
Syndex Bio also announced it has closed an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners, with additional investment from +ND Capital, OMX Ventures, and Meltwind. The funding will be used to expand the mcPCR platform, develop clinical workflows and applications, and grow research operations in Cambridge, UK.
As part of this development, Gautam Kollu, former Chief Commercial Officer of Grail, has joined Syndex Bio’s Board of Directors along with Patrick Weiss (Chairman), Geoff Smith, Sean Kendall, and Eric Moessinger.
"Syndex Bio's mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring," said Geoff Smith, PhD, Founder and CEO of Syndex Bio.
"We're honored to have the support of world‑class investors and advisors as we advance toward clinical translation."
Sean Kendall, Board Member at Syndex Bio and Partner at ARCH Venture Partners added: "This milestone is a testament to Syndex Bio's talented team and their extraordinary efforts in launching this foundational technology. We believe mcPCR holds the potential to elevate the accuracy and speed of cancer screening and diagnosis and look forward to seeing the company continue to go from strength to strength."
Geoff Smith will present further details about mcPCR at AGBT during a poster session scheduled from February 23-26.
